NCT01280695
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 28, 2011
Completion: Jun 30, 2011